TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: This study is designed to examine the efficacy of a cognitive behavioral therapy (CBT) program for treating anxiety symptoms, social problems, and adaptive behavior deficits in children with autism spectrum disorders.


Options:
A: Score on anxiety diagnostic interview after treatment or waitlist (post-treatment); Score on anxiety rating scale after treatment or waitlist (post-treatment)
B: DSM-IV criteria for Separation Anxiety Disorder (December 2009); Global Success Rating (GSR) (December 2009); Separation Anxiety Inventory for Children (SAI) (December 2009)
C: Brief Problem Checklist (BPC, parent and child forms) (Change over time from Day 1 to Day 267)
D: Anxiety Disorders Interview Schedule - Child/Parent Version (Post Treatment (16 weeks))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: This study is designed to examine the efficacy of a cognitive behavioral therapy (CBT) program for treating anxiety symptoms, social problems, and adaptive behavior deficits in children with autism spectrum disorders.


Options:
A: Pediatric Anxiety Rating Scale (After an average of 16 weeks (Post-treatment))
B: Change in Diagnostic severity of social anxiety disorder (ADIS CSR score) (2 week and 6-month follow-up); Change in Treatment response/non-response (a CGI-I of Improved or better, ratings of 1-3, 3 = Improved) (2 week and 6-month follow-up)
C: Score on anxiety diagnostic interview after treatment or waitlist (post-treatment); Score on anxiety rating scale after treatment or waitlist (post-treatment)
D: Pediatric Anxiety Rating Scale. (Post-treatment, which is an average of 16 weeks after Baseline)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Obstructive Sleep Apnea Syndrome
Brief Summary: Hypothesis: Computer controlled continuous positive airway pressure (autoCPAP) is equally effective in improving obstructive sleep apnea syndrome symptoms, breathing disturbances, objective vigilance, and it is cost-effective compared to conventional fixed continuous positive airway pressure.


Options:
A: 30-day mortality (12 months)
B: Sleep apnoea severity, daytime symptoms of sleep apnoea (2 weeks)
C: subjective sleepiness and other OSAS symptoms (3 months, 1 year, 2 years); quality of life (3 months, 1 year, 2 years); percentage of withdrawal and cross-over to other CPAP mode (3 months, 1 year, 2 years); objective vigilance (3 months, 1 year, 2 years); blood pressure (3 months, 1 year, 2 years); cost/utility ratios (3 months, 1 year, 2 years)
D: resident-related preventable adverse events and near misses. (Each resident (subject) will be observed for 1 month.)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Obstructive Sleep Apnea Syndrome
Brief Summary: Hypothesis: Computer controlled continuous positive airway pressure (autoCPAP) is equally effective in improving obstructive sleep apnea syndrome symptoms, breathing disturbances, objective vigilance, and it is cost-effective compared to conventional fixed continuous positive airway pressure.


Options:
A: subjective sleepiness and other OSAS symptoms (3 months, 1 year, 2 years); quality of life (3 months, 1 year, 2 years); percentage of withdrawal and cross-over to other CPAP mode (3 months, 1 year, 2 years); objective vigilance (3 months, 1 year, 2 years); blood pressure (3 months, 1 year, 2 years); cost/utility ratios (3 months, 1 year, 2 years)
B: Sympathetic tone (MSNA) (Change from baseline after one month of intervention)
C: To compare the compliance of auto-CPAP and fixed CPAP in terms of CPAP usage hours.; To compare the clinical efficacy of auto-CPAP and fixed CPAP in terms of pressure level to abolish OSA, Epworth sleepiness scale and quality of life questionnaire.; To compare patient acceptance of the different type of treatment.
D: proportion of participants compliant (at least four hours of use per night for all nights) in the Auto Bilevel group compared to the CPAP group after 90 days of treatment during the investigation. (90 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery
Brief Summary: Minimal invasive treatment (called "endovascular") of the arteries of the lower limb remains problematic, because recurrent disease ("restenosis") frequently leads to recurrent symptoms. As yet, balloon angioplasty remains the recommended strategy to revascularize the superficial femoral artery (artery of the thigh). We investigated whether the use of a vascular endoprosthesis ("stent") improves patients´ outcome.

Study hypothesis: Primary stenting with self expanding nitinol stents may improve patency after endovascular treatment of superficial femoral artery obstructions compared to balloon angioplasty with optional stenting.


Options:
A: Target Lesion Percent Stenosis (1 year)
B: Patency at 12-months (12 months); Percentage of Patients With Freedom From Device and Procedure Related Target Limb Major Amputation or Death Through 30-days Post-procedure and Clinically-driven Target Lesion Revascularization at 12-month (30-Days and 12-Months)
C: In-stent late lumen loss (9 months)
D: Angiographic restenosis at 6 months

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome as well as those at risk of developing ARDS.


Options:
A: Individual Physical Function and Mental Health domains from SF-36 (for participants who complete the phone surveys); 6-minute walk distance and memory evaluation (for participants who attend the study visits) (Measured at Months 6 and 12)
B: Compare the adverse events between mesenchymal stem cell treatment and placebo groups (From day 0 at the start of treatment to day 28.)
C: Number of Ventilator Free Days (VFD) (Determined 28 days after a subject entered the study)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome as well as those at risk of developing ARDS.


Options:
A: N/A
B: Mortality rate (at day 90)
C: All-cause hospital mortality (Randomised patients will be ventilated according to their assigned ventilation strategy for up to 60 days, until they die on the ventilator or are successfully (for >24 hours) liberated from mechanical ventilation.)
D: adherence to our explicit mechanical ventilation protocols; (duration of mechanical ventilation); to measure and understand the reasons for crossovers between groups (duration of mechanical ventilation); to estimate the rate of patient recruitment, and understand barriers to recruitment; to document our ability to achieve close to complete follow-up for mortality and quality of life in the 6 months following enrolment

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Cluster Randomized Educational Intervention to Reduce Inappropriate Prescription Patterns for Elderly Patients in General Practice
Brief Summary: This study will explore the possible effect of a tailored educational intervention towards general practitioners, in order to reduce inappropriate prescription patterns for elderly patients \> 70 years.


Options:
A: Change in antibiotic prescription patterns for respiratory infections (1 year)
B: Incidence of adverse events (count incidence of Pressure Ulcers, Urinary Tract Infections, and Falls (nine months)
C: Changes in a set of predefined quality indicators measuring appropriateness of prescriptions for elderly out-patients (1 year)
D: The difference between groups in the change in parent and nurse ratings of specific communication skills and professionalism behaviors from baseline to follow-up (average 5 months later)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Cluster Randomized Educational Intervention to Reduce Inappropriate Prescription Patterns for Elderly Patients in General Practice
Brief Summary: This study will explore the possible effect of a tailored educational intervention towards general practitioners, in order to reduce inappropriate prescription patterns for elderly patients \> 70 years.


Options:
A: The primary outcome is the proportion of TB cases identified in primary care. The study is powered to detect a 20% increase (from 55% to 75%) in the detection of new cases of TB in primary care with 80% power at the 5% significance level.
B: Changes in a set of predefined quality indicators measuring appropriateness of prescriptions for elderly out-patients (1 year)
C: Hospital rate of permanent colostomy; Hospital rate of local recurrence
D: Adherence to guidelines G10 and G17 of the 2003 International Consensus Guidelines on nonvariceal upper GI bleeding. (1 year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Cluster Randomized Educational Intervention to Reduce Inappropriate Prescription Patterns for Elderly Patients in General Practice
Brief Summary: This study will explore the possible effect of a tailored educational intervention towards general practitioners, in order to reduce inappropriate prescription patterns for elderly patients \> 70 years.


Options:
A: N/A
B: Improvement of drug prescribing (Participants will be followed for the duration of hospital stay, an expected average of 12 days)
C: The primary outcome measure will be the "improvement" of prescribing for efficacious therapies in patients with a chronic cardiovascular disease within six months of the intervention.
D: Changes in a set of predefined quality indicators measuring appropriateness of prescriptions for elderly out-patients (1 year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: B-Unaware Study: Comparison of BIS-guided Anesthesia With End-Tidal Volatile-Guided Anesthesia to Decrease The Incidence of Awareness During High-Risk Surgery
Brief Summary: The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during surgery. The BIS monitor may be able measure how asleep a patient is during surgery. Using the BIS monitor to guide anesthesia will be compared with using the concentration of anesthetic gas to guide anesthesia.


Options:
A: Incidence of postoperative delirium (During the first 7 days after surgery.)
B: Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry (At PACU entry on Day 1)
C: The incidence of explicit recall of events during the surgical and anesthetic periods. (30 days)
D: incidence of delirium (days in hospital)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: B-Unaware Study: Comparison of BIS-guided Anesthesia With End-Tidal Volatile-Guided Anesthesia to Decrease The Incidence of Awareness During High-Risk Surgery
Brief Summary: The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during surgery. The BIS monitor may be able measure how asleep a patient is during surgery. Using the BIS monitor to guide anesthesia will be compared with using the concentration of anesthetic gas to guide anesthesia.


Options:
A: Time to extubation since the interruption in the administration of anaesthetics. (30 minutes-3 hours)
B: The Percentage of Incidences With Explicit Recall in the BIS Versus MAC Alert Groups. (Outcome of awareness is assessed 30-days after the operation)
C: The incidence of explicit recall of events during the surgical and anesthetic periods. (30 days)
D: Bispectral index (BIS) monitoring in abdominal surgery patients (six months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: B-Unaware Study: Comparison of BIS-guided Anesthesia With End-Tidal Volatile-Guided Anesthesia to Decrease The Incidence of Awareness During High-Risk Surgery
Brief Summary: The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during surgery. The BIS monitor may be able measure how asleep a patient is during surgery. Using the BIS monitor to guide anesthesia will be compared with using the concentration of anesthetic gas to guide anesthesia.


Options:
A: evaluation of intra-operative awareness in all the patients investigated (within 4 days after the general anesthesia)
B: The incidence of explicit recall of events during the surgical and anesthetic periods. (30 days)
C: The primary endpoint is hospital length of stay (LOS), defined from the start of surgery until actual hospital discharge. Patients transferred to another hospital will be tracked until final discharge to home (or other final destination). LOS is likely
D: electroencephalographic (BIS) and functional cognitive recovery (24h)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: B-Unaware Study: Comparison of BIS-guided Anesthesia With End-Tidal Volatile-Guided Anesthesia to Decrease The Incidence of Awareness During High-Risk Surgery
Brief Summary: The overall purpose of this study is to see if a Bispectral Index (BIS) monitor, a Food and Drug Administration (FDA) approved brain monitoring device, will help to reduce the risk of patients remembering being awake during surgery. The BIS monitor may be able measure how asleep a patient is during surgery. Using the BIS monitor to guide anesthesia will be compared with using the concentration of anesthetic gas to guide anesthesia.


Options:
A: The Primary Endpoint is a Composite of Death and Cardiovascular Events (Clinical and Silent MI, Cardiac Failure, Cardiac Arrest, Pulmonary Embolism, and Stroke) Measured at 30 Days After Surgery. (30 days post op)
B: The incidence of explicit recall of events during the surgical and anesthetic periods. (Three years)
C: The incidence of explicit recall of events during the surgical and anesthetic periods. (30 days)
D: The primary endpoint is hospital length of stay (LOS), defined from the start of surgery until actual hospital discharge. Patients transferred to another hospital will be tracked until final discharge to home (or other final destination). LOS is likely

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: Progression-free Survival (PFS) (Median observation time at time of analysis was approximately 21 months); Final Analysis: Time to Progression-free Survival Event (Median observation time was approximately 66.4 months)
B: Progression Free Survival (PFS) (up to 50 months); Number of Participants With a Response (7 months)
C: Overall Survival (OS) (Up to approximately 11 years)
D: Number of Participants (Par.) Classified as Responders and Non-responders for Objective Response as Assessed by an Independent Endpoint Review Committee (IRC) in Accordance With the National Cancer Institute Working Group (NCIWG) 1996 Guidelines (Start of treatment (Week 0 of Visit 2) until Week 24)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: Progression-free Survival (PFS) (Median observation time at time of analysis was approximately 21 months); Final Analysis: Time to Progression-free Survival Event (Median observation time was approximately 66.4 months)
B: Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B (IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.)
C: Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR) (Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021))
D: Progression-free Survival (PFS) Rate at 3 Years (Assessed every 3 months until progression up to 4 years and 8 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: Major Adverse Cardiac and Cerebrovascular Events (MACCEs) (up to 90 days after surgery)
B: Progression-free Survival (PFS) (Median observation time at time of analysis was approximately 21 months); Final Analysis: Time to Progression-free Survival Event (Median observation time was approximately 66.4 months)
C: For our first objective (i.e., the incidence of major perioperative vascular events) our primary outcome is major vascular events (i.e., a composite of vascular death, nonfatal myocardial infarction, nonfatal cardiac arrest, and nonfatal stroke) (30 days post surgery.)
D: Diagnostic accuracy of DES vs. CTCA in the prediction of the postoperative hard cardiac events in patients undergoing intermediate to high risk noncardiac surgeries (1 month)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: N/A
B: Number of Participants (Par.) With Complete Remission (CR), Measured From Start of Treatment Until 3 Months After Last Infusion (Start of treatment (Day 1 of Week 0) until 3 months after start of last infusion (up to Week 32)); Number of Participants (Par.) Who Were Classified as Responders and Non-responders (From start of treatment (Day 1 of Week 0) until 3 months after start of last infusion (up to Week 32))
C: Progression-free Survival (PFS) (Median observation time at time of analysis was approximately 21 months); Final Analysis: Time to Progression-free Survival Event (Median observation time was approximately 66.4 months)
D: Progression-Free Survival (PFS), as Assessed by the Independent Review Committee (IRC) (From randomization to the date of first documented disease progression or death due to any cause, whichever occured first, reported between day of first patient randomized up to about 49 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Internet and Telephone Counseling for Smoking Cessation
Brief Summary: RATIONALE: Computer-assisted stop-smoking plans and telephone counseling may help people stop smoking. It is not yet known which computer-based smoking cessation program is more effective with or without telephone counseling in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying two different computer-based smoking cessation programs to compare how well they work with or without telephone counseling in helping smokers quit smoking.


Options:
A: Blood Pressure, Health-Related Quality of Life(Medical outcome Study Short Form-36) (Baseling, 12month, 24month)
B: Smoking abstinence as measured by 7-day point prevalence abstinence at 12 months following treatment (12 months)
C: Quit line re-enrollment (At 6 months)
D: Child Urine Cotinine (up to 12 months); Parent-reported Second-hand Smoke Exposure in Cigarettes Per Day From All Sources (up to 12 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Internet and Telephone Counseling for Smoking Cessation
Brief Summary: RATIONALE: Computer-assisted stop-smoking plans and telephone counseling may help people stop smoking. It is not yet known which computer-based smoking cessation program is more effective with or without telephone counseling in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying two different computer-based smoking cessation programs to compare how well they work with or without telephone counseling in helping smokers quit smoking.


Options:
A: Our primary outcome measures are patient-reported provider delivered tobacco screening and tobacco cessation advice. (Baseline, 8-months post-intervention, and 24-months post-intervention)
B: 30 day point prevalence of abstinence (6 months)
C: Quit Rate (30-day Follow-Up); Quit Rate (6-Month Follow-Up)
D: Smoking abstinence as measured by 7-day point prevalence abstinence at 12 months following treatment (12 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Internet and Telephone Counseling for Smoking Cessation
Brief Summary: RATIONALE: Computer-assisted stop-smoking plans and telephone counseling may help people stop smoking. It is not yet known which computer-based smoking cessation program is more effective with or without telephone counseling in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying two different computer-based smoking cessation programs to compare how well they work with or without telephone counseling in helping smokers quit smoking.


Options:
A: smoking abstinence: self reported abstinence (12 or more months) (12 months)
B: Smoking cessation (point prevalence, both self reported as biochemical verified) (12 months)
C: Smoking abstinence as measured by 7-day point prevalence abstinence at 12 months following treatment (12 months)
D: Reduction in number of cigarettes smoked as measured by the Timeline Follow-back. (Baseline, Pre Counseling Sessions 1-5, Weeks 8, 12, 24)

Answer: C